nach oben

Erschienen in:

17.07.2017 | Zertifizierte Fortbildung

Dermatologisches Nebenwirkungsmanagement zielgerichteter Onkologika

Schattenseiten der Targeted Therapy

verfasst von: Janina Below, PD Dr. med. Peter Arne Gerber

Erschienen in: hautnah dermatologie | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zielgerichtete onkologische Therapieregime haben in den letzten Jahren in vielen Indikationen zunehmend an Bedeutung gewonnen. Doch neue Wirkungen kommen meist nicht ohne neue Nebenwirkungen. Oftmals sind diese kutaner Art, wodurch dem Dermatologen eine Schlüsselrolle beim Nebenwirkungsmanagement zukommt.

Hirsch FR et al. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet 2016; 388: 1012–24CrossRefPubMed

Matter A. Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. Cancer Biol Med 2015; 12: 316–27PubMedPubMedCentral

Funakoshi T et al. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis. Cancer Treat Rev 2014; 40: 1221–9CrossRefPubMed

Gutzmer R et al. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dermatol Ges 2011; 9: 195–202

Wacker B et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13: 3913–21CrossRefPubMed

Lichtenberger BM et al. Epidermal EGFR controls cutaneus host defense and prevents inflammation. Sci Transl Med 2013; 5: 199ra111CrossRefPubMed

Gerber PA et al. Density of demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Dermatology 2011; 222: 144–7CrossRefPubMed

Gerber PA et al. Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol 2010; 63: 163–5CrossRefPubMed

Gerber PA et al. Mechanisms of skin aging induced by EGFR inhibitors. Support Care Cancer 2016; 24: 4241–8CrossRefPubMed

10.

Segaert S et al. Skin toxicities of targeted therapies. Eur J Cancer 2009; 45(Suppl 1): 295–308CrossRefPubMed

11.

Gerber PA et al. Images in clinical medicine. Erlotinib-induced hair alterations. N Engl J Med 2008; 358: 1175CrossRefPubMed

12.

Lacouture ME et al. Clinical practice guidelines for the prevention and treatment of EGFR-inhibitor- associated dermatologic toxicities. Support Care Cancer 2011; 19: 1079–95CrossRefPubMedPubMedCentral

13.

Bölke E et al. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 2008; 184: 105–10CrossRefPubMed

14.

Budach W et al. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Eng J Med 2007; 357: 514–5CrossRef

15.

Gerber PA et al. Radiation induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects. J Clin Oncol 2007; 25: 4697–98 (author reply 4698–4699)CrossRefPubMed

16.

Lacouture ME et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 1351–7CrossRefPubMed

17.

Vaubel J et al. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash. J Eur Acad Dermatol Venerol 2014; 28: 1685–9CrossRef

18.

Gerber PA et al. Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. Eur J Med Res 2012; 23: 4CrossRef

19.

Melosky B et al. Management of EGFR TKI-induced dermatologic adverse events. Curr Oncol 2015; 22: 123–32CrossRefPubMedPubMedCentral

20.

Gerber PA et al. The Koebner-phenomenon in epidermal growth factor receptor inhibitor associated cutaneous adverse effects. J Clin Oncol 2008; 26: 2790–2CrossRefPubMed

21.

Jo JC et al. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. Eur J Dermatol 2013; 23: 77–82PubMed

22.

Ocvirk J et al. A review of the treatment options for skin rash induced by EGFR-targeted therapies: evidence from randomized clinical trials and a meta-analysis. Radiol Oncol 2013; 47: 166–75CrossRefPubMedPubMedCentral

23.

Gerber PA et al. More on aprepitant for erlotinib-induced pruritus. N Engl J Med 2011; 364: 486–7CrossRefPubMed

24.

Santini D et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 2012; 13: 1020–4CrossRefPubMed

25.

Lupu I et al. Cutaneous complications of molecular targeted therapy used in oncology. J Med Life 2016; 9: 19–25PubMedPubMedCentral

26.

Rosenbaum SE et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008; 16: 557–66CrossRefPubMed

27.

Akanay-Diesel S et al. Sunitinib inuced pyoderma gangraenosum-like ulcerations. Eur J Med Res 2011; 16: 491–4CrossRefPubMedPubMedCentral

28.

Kong HH et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007; 56: 171–2CrossRefPubMedPubMedCentral

29.

Degen A et al. The hand- foot-syndrome associated with medical tumor therapy — classification and management. J Dtsch Dermatol Ges 2010; 8: 652–61PubMed

30.

Miller KK et al. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014; 71: 787–94CrossRefPubMed

31.

Vincenzi B et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15: 85–92CrossRefPubMedPubMedCentral

32.

Hofheinz RD et al. Mapisal versus urea cream as prophylaxis for capecitabine- associated hand-foot syndrome: a randomized phase III trial of the AIO quality of life working group. J Clin Oncol 2015; 33: 2444–8CrossRefPubMed

33.

Scotte F et al. Multicenter study of a frozen glove to prevent docetaxel- induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005; 23: 4424–9CrossRefPubMed

34.

Curtin JA et al. Distinct sets of genetic alterations in melanoma. N Eng J Med 2005; 353: 2135–47CrossRef

35.

Robert C J et al. Improved overall survival in Melanoma with combined dabrafenib and trametinib. N Eng J Med 2015; 372: 30–9CrossRef

36.

Zimmer L et al. Incidence of new primary melanoma after diagnosis of stage III and IV melanoma. J Clin Oncol 2014; 32: 816–23CrossRefPubMed

37.

Zimmer L et al. Side effects of systemic oncological therapies in dermatology. J Dtsch Dermatol Ges 2012; 10: 475–86PubMed

38.

Lacouture ME et al. Analysis of dermatologic events in Vemurafenib-treated patients with melanoma. Oncologist 2013; 18: 314–22CrossRefPubMedPubMedCentral

39.

Boussemart L et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013; 24: 1691–7CrossRefPubMed

40.

Dummer R et al. Ultraviolet a and photosensitivity during vemurafenib therapy. N Engl J Med 2012; 366: 480–1CrossRefPubMed

41.

Satzger I et al. Serious skin toxicity with the combination of BRAF-inhibitors and radiotherapy. J Clin Oncol 2013; 31: e220–2CrossRefPubMed

42.

Forschner A et al. Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res 2014; 24: 512–6CrossRefPubMed

43.

Golian E et al. Cutaneous Complications of targeted melanoma therapy. Curr Treat Options Oncol 2016; 17: 57CrossRefPubMed

44.

Meurer M et al. Medikamentöse Therapie des malignen Melanoms. Hautarzt 2012; 63: 885–98CrossRef

45.

Belum VR et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60: 12–25CrossRefPubMedPubMedCentral

46.

Beck KE et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283–9CrossRefPubMedPubMedCentral

47.

Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23CrossRefPubMedPubMedCentral

48.

Lacouture ME et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014; 71: 161–9CrossRefPubMed

49.

Sanlorenzo M et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 2015; 151: 1206–12CrossRefPubMedPubMedCentral

50.

Teulings HE et al. Vitiligo-like depigmentation in patients with stage III–IV melanoma receiving immunotherapy and ist association with survival: a systematic review and meta-analysis. J Clin Oncol 2015; 33: 773–81CrossRefPubMed

Titel: Dermatologisches Nebenwirkungsmanagement zielgerichteter Onkologika
Schattenseiten der Targeted Therapy
verfasst von: Janina Below
PD Dr. med. Peter Arne Gerber
Publikationsdatum: 17.07.2017
Verlag: Springer Medizin
Erschienen in: hautnah dermatologie / Ausgabe 4/2017
Print ISSN: 0938-0221
Elektronische ISSN: 2196-6451
DOI: https://doi.org/10.1007/s15012-017-2305-1

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Jedes dritte Melanom wird auch von Experten übersehen

Keine Lokalbehandlung ohne sporoziden Wirkstoff

Akne: Lactoferrin als Therapiealternative?

Erst der Krebs, dann die Gürtelrose

Akne: neue Lichttherapie-Maske

Von Zebras und Teufelskindern

Leitlinien kompakt für die Dermatologie

Update Dermatologie